Clinical trial
A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+)…
NCT00485277 · Bavarian Nordic, Industry · Completed
Key facts
| NCT number | NCT00485277 |
|---|---|
| Title | A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer |
| Official title | A Phase I Trial of a Fixed Dose of MVA-BN-HER2 Following 1st- or 2nd-Line Chemotherapy for HER-2-Positive Metastatic Breast Cancer |
| Lead sponsor | Bavarian Nordic, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological |
| Interventions | MVA-BN-HER2 |
| Enrollment | 9 |
| Start date | Jun 1, 2007 |
| Primary completion | Sep 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Jun 12, 2007 |
| Last update posted | Mar 14, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: